Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.
Also called NCT07820111
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 159 participants
- Sponsor
- Zagazig University
- Registry
-
NCT07820111
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Saudi Arabia
- Registry status
- Completed
Technical summary
Registry record NCT07820111. Randomized; no masking; primary purpose treatment. Start 2025-10-18 (actual); primary completion 2026-03-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
- Condition
- Obese Diabetics
- Condition
- Obese Non Diabetic
- Intervention (Drug)
- Dulaglutide 1.5 MG/ML
- Intervention (Drug)
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Intervention (Drug)
- Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
- Intervention (Drug)
- Dulaglutide 0.75mg subcutaneous injection
- Intervention (Drug)
- Semaglutide 1.0 mg
- Intervention (Drug)
- Tirzepatide (Flexible titration)
- Lead sponsor
- Zagazig University
Record details
- Record id
cardio:ct-nct07820111- Content hash
5b661f50400364b854c58131abb023f3f487805a9d8ea2440f0e16779f83e40c